NCCN 2021 GLOBAL PROGRAMMING 2021 Business Development … · RRR and Mobile App. In 2019, the NCCN...
12
NCCN.org/global > Global Corporate Council > Global Initiatives > NCCN Global Academy for Excellence & Leadership in Oncology™ > Licensing and Permissions > Distribution of NCCN Content > NCCN eBulletin: Global Edition Advertising > Website and Mobile Application Sponsorships > Business Insights > U.S. Programming NCCN 2021 GLOBAL PROGRAMMING GLOBAL
Transcript of NCCN 2021 GLOBAL PROGRAMMING 2021 Business Development … · RRR and Mobile App. In 2019, the NCCN...
NCCN.org/global
> Global Corporate Council
> Global Initiatives
> NCCN Global Academy for Excellence & Leadership in Oncology™
> Licensing and Permissions
> Distribution of NCCN Content
> NCCN eBulletin: Global Edition Advertising
> Website and Mobile Application Sponsorships
> Business Insights
> U.S. Programming
NCCN 2021 GLOBAL PROGRAMMING
GLOBAL
Contact Information
GLOBAL
NCCN’s Global Corporate Council membership, please contact:Tracy McDowell Manager, Global Business Development [email protected]
Caitlin McAuley Project Manager, Global Business Development [email protected]
NCCN.org/global
NCCN Global Corporate CouncilInternational collaborations are a vital part of the development of the NCCN Global Program. In order to advance its Mission, NCCN works with various stakeholders in health care, including industry, to identify programming and execute on opportunities that will have a global impact. The NCCN Global Corporate Council is a membership opportunity for industry that serves to build relationships and facilitate collaboration, and thus, better serve patients. Global membership may be customized with any of the non-CE programming opportunities highlighted in this prospectus.
Sample benefits to a Global Corporate Council membership may include*:
• Attendance at annual Global Corporate Council Meeting
• Complimentary registration to NCCN Symposia
• Complimentary tuition to NCCN Global Academy
• Global 101 Webex
• Subscriptions to NCCN Flash Updates™
• Access to customizable Global Usage Reports
• Bi-monthly Global Corporate Council newsletter
• Advertisements in the NCCN eBulletin: Global Edition
• Permission to link to the International Adaptations & Translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Table of Contents Web Page
• Recognition of Global Corporate Council membership at NCCN Annual Conference and NCCN Annual Congress: Hematologic Malignancies™
• Acknowledgment on the NCCN website: NCCN.org/global/supporters
• Access to annual NCCN Guidelines User Survey global report
• NEW! Exclusive access to new NCCN Virtual Global Content
Additional items may be included to customize your membership:
• NCCN Rapid Response General Mission Support
• Sponsorship of Virtual Library of NCCN Guidelines® Mobile App
• License to use NCCN Guidelines® content in promotional and educational materials.
• NCCN Pocket Guides: International Edition or NCCN Guidelines & NCCN Compendia®: Flash Cards
• Support for NCCN Global Roundtable
• NCCN International Trends™ Survey questions
*The above benefits are examples of programming that can be included in a membership. Memberships are not limited to the benefits listed above nor are the benefits included in all memberships. NCCN imposes strict policies to shield the NCCN Guidelines development processes from improper influences because of the importance of the guidelines, guidelines credibility and their impact.
A Corporate Council membership option is also available if your organization has a focus in the United States.
GLOBAL CORPORATE COUNCIL
NCCN Global
Corporate Council
NCCN.org
Contact Information
GLOBAL
For additional information regarding NCCN’s Global Initiatives, please contact:Tracy McDowell Manager, Global Business Development [email protected]
Caitlin McAuley Project Manager, Global Business Development [email protected]
NCCN.org/global
Global Initiatives
“From the 500,000 registered users in the United States to the five in Togo, we are honored to play a part in upholding NCCN’s mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives,” Dr. Robert W. Carlson, NCCN CEO.
To ensure that providers and patients have access to the most up-to-date standards in cancer care, NCCN is committed to maintaining and growing its global resources.
Translation of NCCN Content
Nearly half of the more than 1.2 million registered users of NCCN.org report that they live outside the United States. In order to ensure accessibility of its resources, NCCN is working to bridge language barriers to NCCN recommendations by growing and maintaining a free library of translations of NCCN Guidelines, NCCN Guidelines for Patients®, and other NCCN Resources. These translations are published on NCCN.org as well as within the NCCN mobile application.
As a part of this effort, NCCN offers the opportunity to support translation and maintenance of translations of NCCN Resources. Having such resources available for healthcare professionals can aid in growing disease awareness and supporting organizations have the opportunity to distribute or support NCCN’s distribution of the translated NCCN Content.
NEW! NCCN Rapid Response General Mission Support
NCCN is seeking support to deliver NCCN resources to providers and patients helping them quickly and effectively navigate disruptions in the oncology ecosystem. This support will facilitate physicians’ needs allowing them to focus on providing the best possible care for cancer patients in times of crisis.
Global Roundtables
Discussion across multiple stakeholders is vital to understanding the current state of oncology care, identifying gaps, and enacting meaningful change for the future. NCCN understands this importance, particularly when working across national lines and in a truly comprehensive, global capacity. In order to advance its Mission and Vision, NCCN hosts Global Roundtables of experts across multi-discipline institutions on various topics relevant to advancing high-quality, global cancer care.
Global Leadership Exchange
NCCN offers the opportunity to support a global leadership exchange which allows for clinicians and/or administrators from around the world to observe and interact with NCCN Faculty at an NCCN Member Institution and/or for NCCN Faculty to travel abroad for a clinical exchange.
GLOBAL INITIATIVES
Contact Information
For additional information regarding NCCN Global Academy, please contact:Tracy McDowell Manager, Global Business Development [email protected]
Caitlin McAuley Project Manager, Global Business Development [email protected]
NCCN Global Academy for Excellence & Leadership in Oncology™:
School of Pharmaceutical & Biotech BusinessPharmaceutical and biotechnology professionals are given the rare opportunity to view the global oncology space, its future and its current operational issues from the provider, payer, and patient advocate perspective. Participants will improve their working knowledge of key global business, policy, informational, and operational issues in oncology and will gather valuable insights to develop effective strategies for navigating the various constituencies in consideration of worldwide cancer care issues. Through this interactive program, pharmaceutical and biotech professionals will learn from key stakeholders what they view to be the most pressing issues in the global oncology environment and how to apply this knowledge to create mutually successful working relationships. Professionals from marketing, sales, advocacy, medical affairs, clinical research, international programs, policy and government affairs, and other business areas will better be able to serve their customers with improved knowledge of real-world oncology issues after completion of this program.
To learn more about the NCCN Global Academy program, visit NCCN.org/globalacademy.
NCCN GLOBAL ACADEMY
NCCNHEA
LT
H CARE LEADERSHIP
ONCOLOGY EXCELLENCE
A C A D E M Y
ONCOLOGY EXCELLENC
E
HE
ALT
H C
ARE
LEADE
RS
HIP
NCCN.org/globalacademy
Contact Information
GLOBAL
If you or your organization would like to license NCCN Content for any purpose, please contact: Elyse Desjardins, MBASenior Manager, Business [email protected]
Licensing and Permissions NCCN regularly licenses with companies and organizations for permission to distribute copies of NCCN Content, as well as for use of the NCCN Content in educational and promotional materials, including slide decks, advertisements, and computer based materials. NCCN Content is a highly-valued and trusted resource for health care professionals. Utilizing NCCN Content helps bring credibility to marketing and educational materials.
If you or your organization would like to license NCCN Content for any purpose, please visit NCCN.org/permissions to make a formal submission.
Licensing in Health Information TechnologyNCCN works with organizations for use of content within Health Information Technologies (HIT), including but not limited to clinical decision support and mobile applications for use at point-of-care, and as a standard for medical appropriateness review. NCCN works to inform and regularly notify licensing organizations of updates to the NCCN Content contained in the technologies to ensure that the NCCN Content represented in the tools is up-to-date and consistent with what is published on NCCN.org.
NCCN Content is a valuable asset of NCCN and is subject to copyright, trademark and other legal protections. NCCN Content may not be used, copied, distributed or modified in any manner without a written license agreement from NCCN. NCCN works with organizations interested in using NCCN Content through the NCCN permissions process.
LICENSING AND PERMISSIONS
NCCN.org/global
Contact Information
For additional information regarding NCCN’s Global Programming, please contact:Tracy McDowell Manager, Global Business Development [email protected]
Caitlin McAuley Project Manager, Global Business Development [email protected]
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
NCCN Guidelines® and derivative products are widely recognized and used as the standard for clinical policy in oncology in both the academic and community settings and significantly influences appropriate practice patterns and prescribing behavior. The influence of NCCN Content continues to gather momentum throughout all regions of the world, with over 11.3 million copies of the NCCN Guidelines downloaded worldwide. Distribution of NCCN Content provides health care professionals with a valuable resource.
NCCN Pocket Guides: International Edition Pocket-sized, spiral-bound copies of English and translated versions of the NCCN Guidelines and other NCCN Global Resources for distribution outside of the United States. NCCN Global Resources include but are not limited to regional adaptations of NCCN Guidelines, NCCN Harmonized Guidelines™, and NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™). NCCN Pocket Guides serve as a valuable reference tool and allow clinicians to reference the NCCN Guidelines in making treatment decisions more easily, as well as to have more informed conversations with patients at the point of care. Pocket Guides are printed on quality gloss stock for durability and have coil spines so that algorithms can be viewed as two-page spreads. The International Editions are priced to account for international marketing plans that span multiple countries - taking into account smaller populations sizes and multiple languages. An organization has the opportunity to license for distribution or support NCCN’s distribution.
NCCN Guidelines, Compendia, and Templates: Flash Cards NCCN will develop a customized NCCN-branded Flash Card with Templates selected pages from the NCCN Guidelines and/or NCCN Compendia® and/or NCCN Templates®. The Flash Card is a quick-reference tool for clinicians that aids them in their implementation of the NCCN Guidelines, Compendia, and/or Templates. The Flash Card is compliant with the current PhRMA code and meets the criteria to be considered an appropriate educational item.
DISTRIBUTION OF NCCN CONTENT
1
NCCN Guidelines Version 2.2017Myeloproliferative Neoplasms
NCCN Guidelines IndexTable of Contents
Discussion
Version 2.2017, 10/19/16 © National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
TREATMENT FOR LOW-RISK MYELOFIBROSIS
Asymptomatic
Symptomaticl,m
ObservationorClinical trial
Ruxolitinibn
or Interferons (Interferon alfa-2b, pegylated interferon alfa-2a, and pegylated interferon alfa-2b)orClinical trial
MPN-2
Low risk Risk score = 0IPSS DIPSS and DIPSS-Plusk
Assess symptom burden using MPN-SAF TSS-10 itemsl if not done previously
Monitor for signs and symptoms of disease progression every 3–6 monthsl,o,p
Asymptomatic
Symptomaticl,m
kDynamic International Prognostic Scoring System (DIPSS)-Plus is preferred for the risk stratification of myelofibrosis; however, IPSS should be used at diagnosis. DIPSS can be used for risk stratification, if karyotyping is not available. See Risk Stratification for Patients with Myelofibrosis (MPN-F).
lSee Assessment of Symptom Burden (MPN-C 3 of 3).mSee Supportive Care (MPN-G).nSee Special Considerations for the Use of Ruxolitinib (MPN-H).oBone marrow aspirate and biopsy should be performed at diagnosis and as
clinically indicated (if supported by increased symptoms and signs of progression).
pSee 2013 IWG-MRT and ELN Response Criteria for MF (MPN-I).qDisease progression to intermediate-risk 1 (INT-1) or intermediate-risk 2 (INT-2)/
high-risk should be managed as outlined on MPN-3 and MPN-4. See MPN-6 for disease progression to accelerated or blast phase MF or AML.
rClinical benefit may not reach the threshold of the 2013 IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. See 2013 IWG-MRT and ELN Response Criteria for MF (MPN-I).
Monitor responsep and signs/symptomsof disease progression every 3–6 monthsl,o
Response
No Response or Loss of response
Disease progressionq
Continue prior treatmentn,r
INT-1, See MPN-3, INT-2/High risk, see MPN-4, and Advanced stage MF, see MPN-6
Note: All recommendations are category 2A unless otherwise indicated.Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Drugs & Biologics Compendium (NCCN Compendium®)
Enfortumab vedotin-ejfvOverall management of Bladder Cancer from diagnosis through recurrence is described in the complete version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer.
Reproduced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Bladder Cancer V.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Version 2020
continued on next pageNCCN.org/global
2019年第2版 04/08/19 著作権 © 2019 National Comprehensive Cancer Network® (NCCN®) 無断転載を禁止する。NCCN®の明示の書面による許諾なく、本ガイドラインおよびここに含まれるイラストを複製することは、いかなる形態においても禁じられている。
33
免免疫疫療療法法関関連連毒毒性性 のの管管理理
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) （NCCN腫瘍学臨床診療ガイドライン）
2019年 第 2版 ― 2019年 4月 8日 NCCN.org
Contact Information
For additional information regarding distribution of NCCN Content, please contact:Tracy McDowell Manager, Global Business Development [email protected]
Caitlin McAuley Project Manager, Global Business Development [email protected]
NCCN Guidelines for Patients®
NCCN aims to provide state-of-the-art cancer treatment information in easy-to-understand language for people with cancer and the general public. NCCN Guidelines for Patients are translations of the NCCN Guidelines that are meant to help people with cancer talk with their physicians about the best treatment options for their disease. With support from NCCN Foundation® and generous donors, NCCN continues to expand the library of NCCN Guidelines for Patients to include additional disease sites, areas of cancer care, and language translations. NCCN seeks support for the distribution and translation of NCCN Guidelines for Patients to share important information to people when they are diagnosed with cancer.
Sponsorship of the NCCN Guidelines Formatted for Smartphone and Tablet ComputersThis easy-to-use and convenient format further assists health care professionals in their implementation of the NCCN Guidelines, thus improving the quality and effectiveness of care provided to patients with cancer. Sponsorship includes copies of a promotional card containing instructions to access the new and improved version of the Virtual Library of NCCN Guidelines app and/or a QR code that allows users to download the specified NCCN Guideline directly to their mobile device, for your company’s distribution to health care professionals. The app is available free-of-charge for Apple and Android devices.
DISTRIBUTION OF NCCN CONTENT
continued from previous page
NCCN.org/global
GLOBAL
Contact Information
To learn how to place an ad or determine availability, please contact:Jennifer Tredwell, MBAVice President, Marketing and Communications [email protected]
NCCN eBULLETIN ADVERTISING
Ad Sizes
Ad Unit Pixel SizeLeaderboard 728 X 90 px
Banner 468 X 60 px
Skyscraper 160 X 600 px
Square** 90 X 90 px
** NCCN eBulletin and NCCN eBulletin: Global Edition only(includes up to 30 words (NCCN eBulletin) or 75 words (Global Edition) of text with links to advertiser pages)
NCCN eBulletin: Global Edition Newsletter AdvertisingDelivered regularly to registered users of NCCN.org, NCCN eBulletinnewsletters share timely news about topics spanning the globaloncology environment and bridge clinical, policy, and operationalperspectives. NCCN publishes four editions of NCCN eBulletin, each intended for a specialized audience.
• NCCN eBulletin: Global Edition: Clinical and operational trends in the delivery of cancer care and the oncology health policy environment and detailed information on NCCN Global Initiatives, as well as new translations and adaptations of the NCCN Guidelines. Reach more than 309,000 oncology professionals from approximately 197 countries outside of the United States.
Other newsletter editions:• NCCN eBulletin
• NCCN eBulletin: Member Institution Edition
• NCCN eBulletin: Patient Advocacy Edition
NCCN.org/advertising
NCCN.org
GLOBAL
Contact Information
To learn how to sponsor NCCN.org, please contact:Jennifer Tredwell, MBAVice President, Marketing and Communications [email protected]
WEBSITE
NCCN Website Sponsorship — NCCN.org The NCCN website NCCN.org is being completely redesigned in 2020! This robust and comprehensive resource of clinical information, and includes the only online postings of the Complete Library of NCCN Guidelines. In 2019, there were more than 3.5 million unique visitors to NCCN.org and more than 1.2 million individual registered users. Physicians and other medical professionals, as well as patients and their caregivers, regularly visit NCCN.org for highly credible clinical information, including:
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
• NCCN Drugs & Biologics Compendium (NCCN Compendium®)
• NCCN Chemotherapy Order Templates (NCCN Templates®)
• NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™)
• NCCN Biomarkers Compendium®
• NCCN Radiation Therapy Compendium™
• Information and profiles on the 30 NCCN Member Institutions
• NCCN Global Program
• NCCN Oncology Research Program (ORP) Information
• NCCN Oncology Policy Program
• Registration for all NCCN educational programs
• NCCN Virtual Reimbursement Resource Room – enabling readers to learn about patient assistance programs and reimbursement services.
Visitors to NCCN.org include:
• Oncologists from private practice, government, and academic settings
• Oncology fellows
• Nurses
• Pharmacists
• Patients with cancer, their caregivers, and family members
• Health care publishers
Contact Information
GLOBAL
NCCN.org/trends
To learn more about NCCN Trends™ Surveys and Data, to commission a survey, or to discuss a customized survey, please contact:Sherry L. Ulrich, MBA Market Insights Specialist [email protected]
BUSINESS INSIGHTS
Distribution of Respondent Types (n = 188)
DEMOGRAPHICS
Page 1
Results:April 2020
MAINTENANCE THERAPY, ENDOMETRIAL CANCER, MULTIPLE MYELOMA, UROTHELIAL CANCER,
AND BREAST CANCER
g Physician/Surgeon/Oncologist
g Nurse/Oncology Nurse or Clinical Nurse Specialist
g Pharmacist
g Physician Assistant or Nurse Practitioner
g Other Clinician
Note: Percentages may not total 100 because of rounding.© National Comprehensive Cancer Network, Inc. 2020, All Rights Reserved. For Personal Use Only. This report may not be reproduced or distributed beyond personal use in any form without the express written permission of NCCN.
NCCN Trends™ from the National Comprehensive Cancer Network® (NCCN®) surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the April 2020 NCCN Trends™ Survey, which focused on Maintenance Therapy, Endometrial Cancer, Multiple Myeloma, Urothelial Cancer, and Breast Cancer. This survey was sent to International users of NCCN.org.
g Physician/Surgeon/Oncologist
g Nurse/Oncology Nurse or Clinical Nurse Specialist
g Pharmacist
g Physician Assistant or Nurse Practitioner
g Other Clinician
80%
4%
2%
3%
11%
NCCN Trends™ Surveys & Data NCCN Trends™, electronic surveys from NCCN, focus on how clinicians deliver cancer care around the world. NCCN Trends™ Surveys pose questions regarding topics including, but not limited to, patterns of care, and awareness and utilization of various treatment modalities, as well as key topics impacting oncology stakeholders, such as how changes in the health care environment impact them and their patients.
Organizations supply draft questions for each survey. Following review within the NCCN Trends™ team and prior to survey launch, a consultation call may be scheduled to discuss any potential refinements to the questions according to research goals and data needs. The data is then gathered through brief electronic surveys to more than 300,000 health care providers who access the NCCN website on a frequent basis and express interest in responding to NCCN Trends™ Surveys. These clinicians consist of practicing physicians in diverse practice settings, including academic/research cancer centers, community hospitals, and private practices. Survey participants also represent pharmacists, nurses, and other oncology stakeholders.
Global Survey Recipients
Respondent Pool Types
Percentage of Respondent Pool
Clinicians outside of the United States 66%
Subset of clinicians outside of the United States registered as doctors, surgeons, or oncologists
73%
NCCN Trends™ provides detailed analyses of resulting data that can help determine trends and patterns by geographical region, practice size, practice setting, and specialty. In addition, NCCN has the capability of conducting customized surveys to gather insights from clinicians in targeted geographic areas to support research efforts.
NCCN Trends™ Surveys and Data are independent of any NCCN Guidelines or other NCCN clinical recommendations. Participants in the surveys receive a summary of survey results that offer insight into their own practice and that of their peers.
Contact Information
NCCN.org
For additional information regarding NCCN’s US Programming, please contact:Elyse Desjardins, MBASenior Manager, Business [email protected]
US PROGRAMMING
continued on next page
NCCN Oncology Research Program (ORP) The NCCN ORP is a comprehensive program utilizing diverse research platforms and expert scientific advisors to foster the development of leading research to benefit patients with cancer. The NCCN ORP’s core services focus on assisting companies with drug development plans and strategies, facilitating the conduct of preclinical, translational, and clinical research at NCCN Member Institutions, ensuring that results of funded research projects are publicly disseminated.
NCCN Policy Summit Series
The NCCN Oncology Policy Program provides opportunities for discussion among oncology stakeholders to address relevant health policy concerns. Support of NCCN Policy Summits includes recognition of support, invitation(s) to attend, and permission to distribute the resulting article/summit summary.
NCCN Reimbursement Resource Room and Mobile App The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians. As a response to these ongoing challenges, NCCN has strategized to provide access to and information about resources available for clinicians and patients within the reimbursement space. To help clinicians and their staff address reimbursement challenges, NCCN developed: the NCCN Reimbursement Resource Room (RRR) including the NCCN Virtual RRR and Mobile App. In 2019, the NCCN Virtual RRR had more than 12,300 page views. The app, which was updated in 2019 to increase usability, had more than 1,800 users.
Commercial Sponsorships and Exhibitor Opportunities at NCCN MeetingsNCCN Annual ConferencePlanned for: March 18 - 20, 2021 The NCCN Annual Conference attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Guidelines, the data upon which the NCCN Guidelines are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas.
Opportunities include:
• Commercial Level Sponsorships• Exhibit Space• Reimbursement Resource Room Tabletops• Patient Advocacy Pavilion Sponsorship• Exhibitor Showcase Presentations• Exhibition Guide Advertisements & Door Drops• Exhibition Hall Offerings
Contact Information
NCCN.org
continued from previous page
For additional information regarding NCCN’s US Programming, please contact:Elyse Desjardins, MBASenior Manager, Business [email protected]
US PROGRAMMING
NCCN Annual Congress: Hematologic Malignancies™ Planned for: October 15 - 16, 2021The NCCN Annual Congress: Hematologic Malignancies™ attracts more than 500 attendees. The treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of new advances. In addition, targeted therapies and oral treatments bring new benefits to patients. This one-and-a-half day program will feature presentations and panel discussions on patient cases.
Opportunities include:
• Commercial Level Sponsorships• Tabletop Exhibit Space• Patient Advocacy Pavilion Sponsorship• Exhibition Guide Advertising & Door Drops• Exhibition Hall Offerings
